Affiliation:
1. Beijing Jishuitan Hospital, Capital Medical University
2. Peking University Third Hospital
Abstract
Abstract
Background
To evaluate the effectiveness of iguratimod combined with NSAIDs, and bisphosphonates treatment for rapid symptom relief in patients with SAPHO syndrome.
Methods
We recruited all patients seen in our unit from 2018 to 2023 diagnosed with SAPHO syndrome, who were treated with iguratimod combined with NSAIDs, and bisphosphonates, and were followed up for 12 weeks.
Results
A total of 19 patients were included. There were 14(73.7%) women and 5(26.3%) men. The average age was 49.5 years old (ranging from 26 to 67 years). During the follow-up period, a total of 5 patients terminated the experiment. 13/14(92.9%) patients responded favourably to the treatment of iguratimod combined with NSAIDs, and bisphosphonates. Younger patients might be better treated by iguratimod combined with NSAIDs, and bisphosphonates (p = 0.038)
Conclusion
Iguratimod combined with NSAIDs, and bisphosphonates seem to be a very effective mode of therapy in quickly relieving the symptoms of patients with SAPHO syndrome. Iguratimod may be a new choice for the treatment of SAPHO syndrome patients.
Publisher
Research Square Platform LLC
Reference22 articles.
1. [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases] [J];Chamot AM;Rev Rhum Mal Osteoartic,1987
2. The SAPHO syndrome: a clinical and imaging study [J];Salles M;Clin Rheumatol.,2011
3. A case of SAPHO syndrome with diffuse sclerosing osteomyelitis of the mandible treated successfully with prednisolone and bisphosphonate [J];Hatano H;J Oral Maxillofac Surg,2012
4. SAPHO: rare or just not recognized? [J];Doornum S;Semin Arthritis Rheum,2000
5. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis [J];Hayama K;Eur J Dermatol,2010